Washington D.C., – The Angelman Syndrome Foundation (ASF) and the Foundation for Angelman Syndrome Therapeutics (FAST) are hosting the inaugural Angelman Syndrome (AS) Congressional Advocacy Day in Washington, D.C. Angelman syndrome advocates from all corners of the country will head […]
Read more
Angelman Syndrome Foundation (ASF) and Dup15q Alliance proudly announce their strategic partnership to launch the LADDER Learning Network, a new medical network specifically designed for individuals with Angelman syndrome (AS) and dup15q—two rare disorders affecting the q-arm of the […]
Read more
In 2018, the ASF co-funded a feasibility study to test a newborn screening for Angelman syndrome, Prader-Willi syndrome and dup15q syndrome. As always, we thank our generous donors! Your support and belief in the ASF mission makes it possible […]
Read more
FAST, the Foundation for Angelman Syndrome Therapeutics, and ASF, the Angelman Syndrome Foundation, announce a collaboration for a legislative working group focused on furthering the awareness and treatment of Angelman syndrome through legislative advocacy. The legislative working group will continue […]
Read more
The International Angelman Syndrome Alliance (ASA) and the Angelman Syndrome Foundation (ASF) announced a newly formed joint initiative: the Global Community Advisory Board (CAB). They will work together to represent the Angelman community as a unified voice when engaging with […]
Read more
Coronavirus Disease 2019 (COVID-19) Questions and Answers (FAQs) Due to quickly evolving information, recommendations may be subject to change and will be updated as needed. The 15q Clinical Research Network has prepared these FAQs to address concerns from the Angelman/Dup15q […]
Read more
The Angelman Syndrome Foundation is issuing the following statement regarding healthcare legislation in the US because of its impacts on the lives of people with Angelman syndrome and their families. Statement from Angelman Syndrome Foundation Board of Directors: The healthcare […]
Read more